CMS proposes changes to increase Medicaid drug price transparency
The Centers for Medicare & Medicaid Services this week proposed changes to the Medicaid Drug Rebate Program intended to improve manufacturer data integrity and help states verify drug prices. CMS will accept comments on the proposed rule through July 25.
Related News Articles
Headline
The Centers for Medicare & Medicaid Services Dec. 4 announced that drug manufacturers bluebird bio, inc. (manufacturer of Lyfgenia) and Vertex…
Headline
The Centers for Medicare & Medicaid Services Oct. 16 approved section 1115 demonstration amendments which will allow Medicaid and Children's Health…
Headline
The Centers for Medicare & Medicaid Services Sept. 26 released guidance on state compliance with the Early and Periodic Screening, Diagnostic and Treatment…
Headline
The Centers for Medicare & Medicaid Services Aug. 15 released a state funding notice for the Cell and Gene Therapy Access Model. The CGT Access Model will…
Perspective
It’s an understatement to say everything on the national political scene is both unprecedented and unpredictable these days.To state the obvious, there will be…
Headline
The AHA July 25 urged the Centers for Medicare & Medicaid Services to maintain the uninsured rate at 8.7% under the inpatient prospective payment system…